RMTI Rockwell Medical

Richmond Brothers and Mark H. Ravich Issue Detailed Presentation Outlining the Case for Change at Rockwell Medical, Inc.

Richmond Brothers, Inc., a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell” or the “Company”), and Mark H. Ravich, who together with their affiliates beneficially own over 6.1 million shares, or 11.8% of the Company’s outstanding common stock, have issued a presentation outlining the case for change at Rockwell. The presentation is available at http://www.richmondbrothers.com/images/uploads/RMTI_ISS_Deck_-5-4-17.pdf.

In the presentation, Rockwell’s series of failures are addressed, including:

  • Sustained underperformance, evidenced by Rockwell’s share price being down 52.5% over the past 3 years1
  • Poor execution strategy, resulting in failure to monetize promising drugs, with no material sales of Triferic or Calcitriol even after receiving approval to go to market several years ago2
  • A disconnect between leadership and shareholders, demonstrated by broken promises and unrealistic guidance around the timeline of commercial launches for Triferic and Calcitriol; in addition to an unwillingness to accept questions on quarterly earnings calls
  • Egregious executive compensation practices, exhibiting disinterest for shareholder concerns, as Chairman and CEO Robert Chioini’s pay equaled 5.49 and 4.61 times the median of Rockwell’s peers in 2014 and 2015, respectively3
  • Boundless corporate governance flaws including an entrenched & staggered Board with shareholder unfriendly practices

“Now is the time for change at Rockwell. While the Company claims to have taken steps to adjust its compensation plan and has announced certain corporate governance ‘enhancements,’ we believe these actions were clearly motivated by our public involvement and are, in our view, not likely to affect the meaningful change desperately needed at Rockwell,” said David S. Richmond, Chairman of Richmond Brothers, Inc., and Mark H. Ravich. They continued, “It is time for shareholders’ best interests to become a priority at Rockwell. We urge shareholders to vote for our highly-qualified nominee, Mark H. Ravich, who upon election to the Board would seek to develop a fair compensation plan, increase the lines of communication between management and shareholders, and help refresh the Board with individuals who have the experience and skills to lead Rockwell towards a successful future.”

IT IS TIME TO HOLD THE ROCKWELL BOARD ACCOUNTABLE

VOTE THE BLUE PROXY CARD TO ELECT MARK H. RAVICH TODAY

If you have any questions, or require assistance with your vote, please contact Saratoga Proxy Consulting LLC, toll- free at (888) 368-0379, call direct at (212) 257-1311 or email: [email protected]

For more information, and to see other communications and filings from Richmond Brothers and Mark H. Ravich, visit this link: http://www.richmondbrothers.com/time-for-action-at-rmti.

About Richmond Brothers, Inc.

Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994.

About Mark H. Ravich

Mark H. Ravich is a private investor and currently serves as President of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998.

1 Calculated as of 2/20/17, the day prior to Richmond Brothers’ public involvement

2 Over two years since the approval of Triferic and more than three years since the approval of Calcitriol

3 ISS reports for Rockwell’s 2015 and 2016 annual meetings

EN
05/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rockwell Medical

 PRESS RELEASE

Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...

 PRESS RELEASE

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...

 PRESS RELEASE

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch